Donghang Cheng, Ph.D.
Department of Pediatrics, Division of Pediatrics
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Pediatrics, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
Studies indicate that arginine methylation is an important posttranslational modification that has been implicated in nuclear export, mRNA splicing, transcriptional control, and DNA repair. Recently, more evidence has linked this modification to carcinogenesis and metastasis. The focus of my research is to investigate the biological role of arginine methylation and develop specific protein arginine methyltransferase inhibitors as valuable tools for probing protein functions and therapeutic agents. Thus, my research is divided into three projects: 1) Functional analysis of PRMT6, 2) Characterizing the role of the transcriptional regulator PRMT6 in small cell lung cancer (SCLC), and medulloblastoma (MB), and 3) I am particularly excited to learn to perform pre-clinical studies and work towards clinical translation of my findings. My goal is to identify PRMT6 as a new target to develop its inhibitor for SCLC and MB treatment. Finally, I am putting efforts into developing imaging tools to monitor the fate of therapeutically administered immune cells. This project has allowed me to develop unique surgical methods for the implantation of tumor xenografts in the mouse lung and brain.
Education & Training
Degree-Granting Education
| 2001 | National Center for Drug Screening Shanghai Institute of Materia Medica, Shanghai, CN, Ph.D. in Pharmacology |
| 1997 | Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai, CN, M.S. in Pharmacology |
| 1990 | Liaoning University, Shenyang, CN, BS in Biology |
Postgraduate Training
| 2001-2004 | Research Fellowship, The University of Texas MD Anderson Cancer Center Science Park-Research Division, Smithville, Texas |
Experience & Service
Academic Appointments
Assistant Professor, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2018 - 2023
Assistant Professor, Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX, 2011 - 2018
Instructor, Department of Epigenetics and Molecular Carcinogenesis, The University of Texas M. D. Anderson Cancer Center, Smithville, TX, 2007 - 2011
Administrative Appointments/Responsibilities
Faculty Senator, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2025
Other Appointments/Responsibilities
Vertebrate Animals Management Lead, Division of Pediatrics during Covid shut down of research operations, Houston, TX, 2020 - 2020
Honors & Awards
| 2006 | Performance Reward, MD Anderson Cancer Center |
| 1997 | Second prize of the "DIAO" Scholarship for Outstanding Graduate Students, Shanghai Institute of Materia Medica |
| 1997 | Third prize of the first JIU-Yuan scholarship from "JIA-ZHEN TAN Life Science Foundation" for Outstanding Graduate Students, "JIA-ZHEN TAN" Life Science Foundation |
| 1994 | Director Scholarship for Outstanding Graduate Student, SIMM, Shanghai Institute of Materia Medica |
| 1987 | Outstanding Undergraduate Student Scholarship, Liaoning University |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Sehl OC, Cheng D, gopalakrishnan V. Preclinical and Clinical-Scale Magnetic Particle Imaging of Natural Killer Cells: in vitro and ex vivo Demonstration of Cellular Sensitivity, Resolution, and Quantification. Mol Imaging Biol, 2024. e-Pub 2024. PMID: 39653984.
- Singh, A, Cheng, D, Swaminathan, J, Yang, Y, Zheng, Y, Gordon, N, Gopalakrishnan, V. REST-dependent downregulation of von Hippel-Lindau tumor suppressor promotes autophagy in SHH-medulloblastoma. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38866867.
- Gao G, Hausmann S, Flores NM, Benitez AM, Shen J, Yang X, Person MD, Gayatri S, Cheng D, Lu Y, Liu B, Mazur PK, Bedford MT. The NFIB/CARM1 partnership is a driver in preclinical models of small cell lung cancer. Nat Commun 14(1):363, 2023. e-Pub 2023. PMID: 36690626.
- Wang M, Fan Y, Fang S, Cui T, Cheng D. A Joint Automatic Modulation Classification Scheme in Spatial Cognitive Communication. Sensors (Basel) 22(17), 2022. e-Pub 2022. PMID: 36080956.
- Cheng D, Fan Y, Fang S, Wang M, Liu H. ResNet-AE for Radar Signal Anomaly Detection. Sensors (Basel) 22(16), 2022. e-Pub 2022. PMID: 36016010.
- Gong S, Maegawa S, Yang Y, Gopalakrishnan V, Zheng G, Cheng D. Licochalcone A is a Natural Selective Inhibitor of Arginine Methyltransferase 6. Biochem J 478(2):389-406, 2021. e-Pub 2020. PMID: 33245113.
- Cheng D, Gao G, Di Lorenzo A, Jayne S, Hottiger MO, Richard S, Bedford MT. Genetic evidence for partial redundancy between the arginine methyltransferases CARM1 and PRMT6. J Biol Chem 295(50):17060-17070, 2020. e-Pub 2020. PMID: 33008887.
- Veazey KJ, Cheng D, Lin K, Villarreal OD, Gao G, Perez-Oquendo M, Van HT, Stratton SA, Green M, Xu H, Lu Y, Bedford MT, Santos MA. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas. Leukemia 34(12):17, 2020. e-Pub 2020. PMID: 32576962.
- Cheng D, Vemulapalli V, Lu Y, Shen J, Aoyagi S, Fry CJ, Yang Y, Foulds CE, Stossi F, Treviño LS, Mancini MA, O'Malley BW, Walker CL, Boyer TG, Bedford MT. CARM1 methylates MED12 to regulate its RNA-binding ability. Life Sci Alliance 1(5):e201800117, 2018. e-Pub 2018. PMID: 30456381.
- Bae N, Viviano M, Su X, Lv J, Cheng D, Sagum C, Castellano S, Bai X, Johnson C, Khalil MI, Shen J, Chen K, Li H, Sbardella G, Bedford MT. Developing Spindlin 1 small-molecule inhibitors by using protein microarrays. Nat Chem Biol 13(7):750-756, 2017. e-Pub 2017. PMID: 28504676.
- Gayatri S, Cowles MW, Vemulapalli V, Cheng D, Sun ZW, Bedford MT. Using oriented peptide array libraries to evaluate methylarginine-specific antibodies and arginine methyltransferase substrate motifs. Sci Rep 6:28718, 2016. e-Pub 2016. PMID: 27338245.
- Hu SB, Xiang JF, Li X, Xu Y, Xue W, Huang M, Wong CC, Sagum CA, Bedford MT, Yang L, Cheng D, Chen LL. Protein arginine methyltransferase CARM1 attenuates the paraspeckle-mediated nuclear retention of mRNAs containing IRAlus. Genes Dev 29(6):630-45, 2015. e-Pub 2015. PMID: 25792598.
- Castellano S, Spannhoff A, Milite C, Dal Piaz F, Cheng D, Tosco A, Viviano M, Yamani A, Cianciulli A, Sala M, Cura V, Cavarelli J, Novellino E, Mai A, Bedford MT, Sbardella G. Identification of small-molecule enhancers of arginine methylation catalyzed by coactivator-associated arginine methyltransferase 1. J Med Chem 55(22):9875-90, 2012. e-Pub 2012. PMID: 23095008.
- Cheng, D, Valente, S, Castellano, S, Sbardella, G, Di Santo, R, Costi, R, Bedford, MT, Mai, A. Novel 3,5-bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors. Journal of Medicinal Chemistry 54(13):4928-4932, 2011. e-Pub 2011. PMID: 21612300.
- Cheng D, Valente S, Castellano S, Sbardella G, Di Santo R, Costi R, Bedford MT, Mai A. Novel 3,5-Bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors: Enzyme selectivity and cellular activity. J Med Chem 54(13):4928-32, 2011. e-Pub 2011.
- Cheng D and Bedford MT. Xenoestrogens Regulate the activity of Arginine Methyltransferases. Chembiochem 12(2):323-9, 2011. e-Pub 2011. PMID: 21243720.
- Castellano S, Milite C, Ragno R, Simeoni S, Mai A, Limongelli V, Novellino E, Bauer I, Brosch G, Spannhoff A, Cheng D, Bedford MT, Sbardella G. Design, synthesis and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 1 (AMI-1). ChemMedChem 5(3):398-414, 2010. e-Pub 2010. PMID: 20091730.
- Kim D, Lee J, Cheng D, Li J, Carter C, Richie E, Bedford MT. Enzymatic activity is required for the in vivo functions of CARM1. J Biol Chem 285(2):1147-52, 2010. e-Pub 2010. PMID: 19897492.
- Mai A, Cheng D, Bedford MT, Valente S, Nebbioso A, Perrone A, Brosch G, Sbardella G, De Bellis F, Miceli M, Altucci L. epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem 51(7):2279-90, 2008. e-Pub 2008. PMID: 18348515.
- Iberg AN, Espejo A, Cheng D, Kim D, Michaud-Levesque J, Richard S, Bedford MT. Arginine methylation of the histone H3 tail impedes effector binding. J Biol Chem 283(6):3006-10, 2008. e-Pub 2008. PMID: 18077460.
- Yadav N, Cheng D, Richard S, Morel M, Iyer VR, Aldaz CM, Bedford MT. CARM1 promotes adipocyte differentiation by coactivating PPARgamma. EMBO Rep 9(2):193-8, 2008. e-Pub 2008. PMID: 18188184.
- Sayegh J, Webb K, Cheng D, Bedford MT, Clarke SG. Regulation of protein arginine methyltransferase 8 (PRMT8) activity by its N-terminal domain. J Biol Chem 282(50):36444-53, 2007. e-Pub 2007. PMID: 17925405.
- Mai A, Valente S, Cheng D, Perrone A, Ragno R, Simeoni S, Sbardella G, Brosch G, Nebbioso A, Conte M, Altucci L, Bedford MT. Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. ChemMedChem 2(7):987-91, 2007. e-Pub 2007. PMID: 17458842.
- Swiercz R, Cheng D, Kim D, Bedford MT. Ribosomal protein rpS2 is hypomethylated in PRMT3-deficient mice. J Biol Chem 282(23):16917-23, 2007. e-Pub 2007. PMID: 17439947.
- Naeem H, Cheng D, Zhao Q, Underhill C, Tini M, Bedford MT, Torchia J. The activity and stability of the transcriptional coactivator p/CIP/SRC-3 are regulated by CARM1-dependent methylation. Mol Cell Biol 27(1):120-34, 2007. e-Pub 2007. PMID: 17043108.
- Cheng D, Cote J, Shaaban S, Bedford MT. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol Cell 25(1):71-83, 2007. e-Pub 2007. PMID: 17218272.
- El Messaoudi S, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng D, Theillet C, Vandel L, Bedford MT, Sardet C. Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci U S A 103(36):13351-6, 2006. e-Pub 2006. PMID: 16938873.
- Cheng D, Yadav N, King RW, Swanson MS, Weinstein EJ, Bedford MT. Small molecule regulators of protein arginine methyltransferases. J Biol Chem 279(23):23892-9, 2004. e-Pub 2004. PMID: 15056663.
- Cheng D, Shen Q, Nan F, Qian Z, Ye QZ. Purification and characterization of catalytic domains of gelatinase A with or without fibronectin insert for high-throughput inhibitor screening. Protein Expr Purif 27(1):63-74, 2003. e-Pub 2003. PMID: 12509986.
- Cheng, D, Shen, Q, Qian, J, Qian, Z, Ye, QZ. Expression and purification of catalytic domain of human macrophage elastase for high-throughput inhibitor screening. Acta Pharmacologica Sinica 23(2):143-151, 2002. e-Pub 2002. PMID: 11866875.
- Cheng D, Shen Q, Qian J, Qian Z, Ye QZ. Expression, purification, and characterization of active catalytic domain of macrophage elastase for high-throughput screening. Acta Pharmacologica Sinica 23, 2002. e-Pub 2002.
- Cheng, D, Tang, XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacology Biochemistry and Behavior 60(2):377-386, 1998. e-Pub 1998. PMID: 9632220.
- Xiong, ZQ, Cheng, D, Tang, XC. Effects of huperzine A on nucleus basalis magnocellularis lesion- induced spatial working memory deficit. Acta Pharmacologica Sinica 19(2):128-132, 1998. e-Pub 1998. PMID: 10374634.
- Cheng D, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activityes. Pharmacology Biochemistry and Behavior 60:377-386, 1998. e-Pub 1998.
- Xiong ZQ, Cheng D, Tang XC. Effects of huperzine A on nuleus basalis magnocellularis lesion-induced spatial working memory deficit. Acta Pharmacologica Sinica 19:128-132, 1998. e-Pub 1998.
- Cheng, D, Ren, H, Tang, XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. NeuroReport 8(1):97-101, 1997. e-Pub 1997. PMID: 9051760.
- Cheng D, Run H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Nuroreport 8:97-101, 1996. e-Pub 1996.
Other Articles
- Haltom AR, Toll SA, Cheng D, Maegawa S, Gopalakrishnan V, Khatua S Medulloblastoma epigenetics and the path to clinical innovation. J Neurooncol 150(1):35-46, 2020. PMID: 32816225.
Abstracts
- Anjier A, Cheng D. Entinostat enhances NK cell efficacy against osteosarcoma lung metastases by improving cytokine production, trafficking, persistence and cytotoxicity. Journal for ImmunoTherapy of Cancer.
- Cheng D. STUDY OF ARGININE METHYL TRANSFERASES IN MEDULLOBLASTOMA. Neuro-Oncology.
- Martinez G, Cheng D. Optimization of a highly sensitivity 19F MRI probe for NK cell immunotherapy tracking. Joint Annual Meeting ISMRM-ESMRMB & ISMRT 31st Annual Meeting.
- Cheng D. REST AND USP37 CONTROL THE MTORC1-AUTOPHAGY AXIS IN MEDULLOBLASTOMA BY REGULATING RAPTOR DEGRADATION. Neuro-Oncology.
Book Chapters
- Cheng D, Vemulapalli V, Bedford MT. Methods applied to the study of protein arginine methylation. In: Methods Enzymol, 71-92, 2012.
- Lee J, Cheng D, Bedford MT. Techniques in protein methylation. In: Methods Mol Biol, 195-208, 2004.
Selected Presentations & Talks
Regional Presentations
- 2013. PRMT6 Methylates H3R17 and Functions as a Transcriptional Coactivator. Conference. PRMT6 Methylates H3R17 and Functions as a Transcriptional Coactivator. Smithville, TX, US.
- 2003. Small molecule inhibitors of protein arginine methyltransferases. Conference. Small molecule inhibitors of protein arginine methyltransferases. Smithville, TX, US.
- 2002. Identifying Methylated proteins using small pool screening. Conference. Identifying Methylated proteins using small pool screening. Smithville, TX, US.
National Presentations
- 2023. Integrated multi-omics analyses identify synergistic interactions with ONC201 against DIPG. Poster. Smithfield, RI, US.
- 2023. Dynamics of PRC2 recruitment to chromatin in H3K27M DIPG. Conference. Histone and DNA Modifications Gordon Research Conference. Smithfield, RI, US.
- 2023. Rest and usp37 control the mtorc1-autophagy axis in medulloblastoma by regulating raptor degradation. Conference. Pediatric Neuro-Oncology Research Conference. Washington DC, US.
- 2021. Harnessing Cellular Stress for Immune Targeting of DIPGs. Conference. Harnessing Cellular Stress for Immune Targeting of DIPGs. Boston, MA, US.
- 2016. CARM1 Methylates Mediator to promote estrogen receptor regulated transcription. Conference. EpiCypher 2016 Biological & Clinical Frontiers in Epigenetics. San Juan, PR, US.
- 2014. PRMT6 methylates H3R17 and functions as a transcriptional coactivator. Conference. PRMT6 methylates H3R17 and functions as a transcriptional coactivator. Santa Fe, NM, US.
- 2012. PRMT6 Methylates H3R17 and Functions as a Transcriptional Coactivator. Conference. PRMT6 Methylates H3R17 and Functions as a Transcriptional Coactivator. Smithville, TX, US.
- 2010. Characterizing CAS3, a prominent substrate for CARM1. Conference. Characterizing CAS3, a prominent substrate for CARM1. Carefree, AZ, US.
- 2008. Arginine Methyltransferases as Novel Therapeutic Targets. Conference. Arginine Methyltransferases as Novel Therapeutic Targets. Snowmass, CO, US.
- 2006. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA Processing. Conference. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA Processing. Saxtons River, VT, US.
- 2004. Small molecule inhibitors of protein arginine methyltransferases. Conference. Small molecule inhibitors of protein arginine methyltransferases. Austin, TX, US.
- 2004. Small molecule inhibitors of protein arginine methyltransferases. Conference. Small molecule inhibitors of protein arginine methyltransferases. Saxtons River, VT, US.
International Presentations
- 2024. Targeting Lysine-Specific Demethylase 1 for Therapeutic and Immune Sensitization in Medulloblastomas. Conference. FASEB Science Research Conference, Biological Methylation: Fundamental Mechanisms. Porto, PT.
- 2020. Study of Arginine Methyltransferases in Medulloblastoma. Conference. Study of Arginine Methyltransferases in Medulloblastoma. Karuizawa, JP.
- 2018. Investigating the Overlapping Functions of Arginine Methyltransferases, CARM1 and PRMT6. Conference. FASEB. Florence, IT.
- 2016. CARM1 Methylates Mediator to promote estrogen receptor regulated transcription. Conference. Cold Spring Harbor. SuZhou, CN.
- 2014. PRMT6 methylates H3R17 and functions as a transcriptional coactivator. Conference. PRMT6 methylates H3R17 and functions as a transcriptional coactivator. Nassau, BS.
- 2012. PRMT6 Methylates H3 R17 and Functions as a Transcriptional Coactivation. Conference. Cold Spring Harbor. Shuzhou, CN.
Formal Peers
- 2018. Novel Facet of CARM1 in Regulating Estrogen Receptor Mediated Transcription. Invited. Novel Facet of CARM1 in Regulating Estrogen Receptor Mediated Transcription. Edinburg, TX, US.
- 2012. Arginine Methyltransferase 6 (PRMT6), a Gene Transcription Repressor or Activator?. Invited. Arginine Methyltransferase 6 (PRMT6), a Gene Transcription Repressor or Activator?. Shanghai, Shanghai, CN.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Magnetic Particle Imaging for Advanced Cellular Therapy Tracking"(MAG-PACT)” |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | 14347286 |
| Date: | 2025 - 2030 |
| Title: | REST-SOX2 interaction in medulloblastoma for therapeutics and biomarker discovery |
| Funding Source: | NIH |
| Role: | Key |
| ID: | GRANT14347635 |
| Date: | 2025 - 2028 |
| Title: | Equipment: Development of a Preclinical Magnetic Particle Imaging System Tailored for Cancer Cell Therapy |
| Funding Source: | National Science Foundation (NSF) |
| Role: | Co-I |
| ID: | 2509874 |
| Date: | 2025 - 2030 |
| Title: | Childhood and Adolescent/Young Adult Cancer Research Resource (CARE) |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | Co-I |
| Date: | 2025 - 2029 |
| Title: | Neurovascular uncoupling and mitigation in pediatric high-grade gliomas |
| Funding Source: | The University of Texas at Austin and The University of Texas MD Anderson Cancer Center Strategic Collaboration |
| Role: | Co-I |
| Date: | 2024 - 2025 |
| Title: | Pre-Clinical Research of Diffuse Intrinsic Pontine Glioma |
| Funding Source: | University of Texas Foundation |
| Role: | Co-I |
| Date: | 2024 - Present |
| Title: | Novel approach to NK cell therapy for recurrent/refractory pediatric medulloblastoma |
| Funding Source: | NIH |
| Role: | Key |
| Date: | 2024 - Present |
| Title: | Combination immunotherapy for diffuse midline gliomas (DMGs) |
| Funding Source: | ChadTough Defeat DIPG Foundation |
| Role: | Key |
| Date: | 2024 - Present |
| Title: | New approach for osteosarcoma: Enhancing and monitoring NK cell therapy |
| Funding Source: | NIH |
| Role: | Key |
| Date: | 2023 - 2028 |
| Title: | Priming preclinical magnetic particle Imaging (MPI) for brain Tumor NK Cell tracking in Humans (PITCH) |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1R01CA281832-01 |
| Date: | 2022 - 2026 |
| Title: | HDO Imaging is a Quantitative Marker of Cerebral Glucose Oxidation |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1R01EB032376-01A1 |
| Date: | 2022 - 2025 |
| Title: | Repurposing migraine medication for DIPG therapy |
| Funding Source: | Uncle Kory Foundation |
| Role: | CO-I |
| Date: | 2022 - 2022 |
| Title: | Study of PRMT6 in Small Cell Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2022 - 2022 |
| Title: | Study of PRMT6 in Small Cell Lung Cancer |
| Funding Source: | DRP-Lung SPORE grant |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Study of ONC201 as an Immuno-sensitizer for DIPGs |
| Funding Source: | Chance For Hope Foundation |
| Role: | Co-PI |
| Date: | 2021 - 2023 |
| Title: | Study of ING2 in Medulloblastoma |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2020 - 2024 |
| Title: | High sensitivity 19F MRI for clinically translatable imaging of adoptive NK cell brain tumor therapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | CO-I |
| ID: | RP20223 |
| Date: | 2018 - 2024 |
| Title: | Pediatric Solid Tumors Comprehensive Data Resource Core |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Date: | 2017 - 2022 |
| Title: | Cytoskeleton Remodeling by the Epigenetic Machinery |
| Funding Source: | NIH/ Subcontract w/BCM |
| Role: | Co-I |
| ID: | R01OD024715-01 |
| Date: | 2011 - 2013 |
| Title: | Arginine methyltransferase CARM1:Potential therapeutic target for prostate cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R21CA165216-01 |
| Date: | 2011 - 2016 |
| Title: | Molecular Mechanisms and Functions of Epigenetic Regulators |
| Funding Source: | LONESTAR Oncology Network for Epigenetics Therapy and Research |
| Role: | Mentor |
| ID: | RP110471 |
| Date: | 2006 - 2008 |
| Title: | Regulation of Transcriptional Coactivators by Environmental Estrogens |
| Funding Source: | National Institute of Health |
| Role: | Key |
| ID: | 1R21ES015188-01 |
| Date: | 2005 - 2009 |
| Title: | Small Molecule Regulators of Arginine Methyltransferases |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | 5R01CA114116-03 |
| Date: | 2002 - 2016 |
| Title: | The Functional Analysis of the Coactivator CARM1 |
| Funding Source: | NIH/BIDDK |
| Role: | Co-I |
| ID: | DK062248-13 |
| Title: | NK Immunotherapy for DIPG |
| Funding Source: | Children's Cancer Research Fund |
| Role: | Key |
| Title: | REST-driven MB cellular heterogeneity in therapeutics and biomarker development |
| Funding Source: | NIH |
| Role: | Key |
| Title: | Study of REST-context specific therapeutic vulnerability in DIPG |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| Title: | Alternative transcript synthesis in medulloblastoma |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| Title: | REST-SETDB1 in DIPG |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | CO-I |
| Title: | New Approach for Osteosarcoma: Enhancing and Monitoring NK Cell Therapy |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| Title: | Characterizing the role of the transcriptional regulator PRMT6 in tumorigenesis |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| ID: | UTMDACC Institutional Research Grant |
| Title: | CHARACTERIZE THE ROLE OF CARM1 AT SUPER-ENHANCERS |
| Funding Source: | MDACC Center for Cancer Epigenetics |
| Role: | PI |
| ID: | Epigenetic pilot project |
| Title: | Study of ING2 Chromatin Remodeler in Pediatric Brain Tumor |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| ID: | UTMDACC Institutional Research Grant |
| Title: | Arginine methyltransferase CARM1 is a Potential therapeutic target for prostate cancer |
| Funding Source: | Sidney Kimmel Foundation |
| Role: | PI |
Patient Reviews
CV information above last modified March 14, 2025